Abstract:AdipoRon, a small-molecule adiponectin receptor (AdipoR) agonist, has been reported to be implicated in cardiovascular diseases. However, its role in pressure-overload-induced cardiac remodeling is still elusive. To elucidate the role of AdipoRon in the pathogenesis of cardiac remodeling in vivo and vitro, in the left ventricle of human end-stage heart failure, the expression of AdipoR2 is upregulated. Meanwhile, increased expression of AdipoR2 was also observed in mice failing hearts. Oral administration of AdipoRon alleviated cardiac hypertrophy and fibrosis induced by pressure overload, as evidenced by the beneficial change of cross-sectional area of cardiomyocytes, heart weight-to-body weight ratio, gene expression of hypertrophic markers, ventricle collagen ratio, and cardiac function. The AMPKα activation mediated by AdipoRon significantly inhibited AngII-induced TGF-β1 expression and cardiac fibroblast differentiation, and these inhibitory effects were abrogated by treatment with the AMPK inhibitor Compound C. Consistent with the above results, AdipoRon abolished the ability to retard AngII-induced TGF-β1 expression in AMPKα2 −/− cardiac fibroblasts. In AMPKα2 −/− mice subjected to aortic banding, AdipoRon abolished the protective effect, as indicated by increased cross-sectional area, cardiac collagen ratio, and cardiac dysfunction. Our results demonstrated that AdipoR2 expression was markedly increased in the failing hearts. AdipoRon inhibited TGF-β1 expression and myofibroblast differentiation in AMPKα-dependent manner in vitro. In line with the vitro results, AMPKα2 −/− mice markedly abrogated the inhibitory effects of AdipoRon in cardiac remodeling. These results indicated AdipoRon may hold promise of an effective therapy against pressure-overload-induced cardiac remodeling. Key messages • The increased expression of AdipoR2 is observed in human and mice failing hearts, the changeable expression of AdipoR suggests the possible role of AdipoR in cardiac remodeling. • Oral administration of AdipoRon alleviates cardiac hypertrophy and fibrosis induced by pressure overload, and AMPKα activation mediated by AdipoRon significantly inhibited AngII-induced TGF-β1 expression and cardiac fibroblast differentiation. • These findings provide new mechanistic insight and open new therapeutic pathways for heart failure.

Long-Term Activation of Adenosine Monophosphate-Activated Protein Kinase Attenuates Pressure-Overload-Induced Cardiac Hypertrophy

Aliskiren Ameliorates Pressure Overload-Induced Heart Hypertrophy and Fibrosis in Mice

Amp Activated Protein Kinase-Alpha 2 Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction in Mice

AMPK Attenuates Microtubule Proliferation in Cardiac Hypertrophy.

Transient activation of AMPK preceding left ventricular pressure overload reduces adverse remodeling and preserves left ventricular function

Thymoquinone Ameliorates Pressure Overload‐induced Cardiac Hypertrophy by Activating the AMPK Signalling Pathway

AMPK attenuates ventricular remodeling and dysfunction following aortic banding in mice via the Sirt3/Oxidative stress pathway

Adenosine Kinase Regulation of Cardiomyocyte Hypertrophy

Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal Transduction

Adenosine Kinase Attenuates Cardiomyocyte Microtubule Stabilization and Protects Against Pressure Overload-Induced Hypertrophy and LV Dysfunction.

Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery.

Abstract 17221: AMPK Regulation of Microtubule Dynamics in Cardiac Hypertrophy

AdipoRon, an adiponectin receptor agonist, attenuates cardiac remodeling induced by pressure overload

Atrial Natriuretic Peptide Inhibits Cardiomyocyte Hypertrophy Through Mitogen-Activated Protein Kinase Phosphatase-1

Abstract 21116: Adenosine Kinase Regulation of Cardiomyocyte Hypertrophy

The role of AMP-activated protein kinase in the cardiovascular system

Alpha1 catalytic subunit of AMPK modulates contractile function of cardiomyocytes through phosphorylation of troponin I

AMPK Activation Is Indispensable for the Protective Effects of Caloric Restriction on Left Ventricular Function in Postinfarct Myocardium

AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation

AMPK activation attenuates S6K1, 4E-BP1, and eEF2 signaling responses to high-frequency electrically stimulated skeletal muscle contractions

TANK Promotes Pressure Overload Induced Cardiac Hypertrophy <i>via</i> Activating AKT Signaling Pathway